Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution
- PMID: 2557169
- DOI: 10.1007/BF00692355
Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution
Abstract
The pharmacokinetics of intravenous ifosfamide were determined in 16 patients with carcinoma of the bronchus. In all 25% (4) of these patients were obese (i.e. greater than 20% over their ideal body weight). The terminal elimination half-life (t1/2 beta) was found to be higher in the obese group than in the control group (6.36 h, range 5.77-7.45 h) vs 4.95 h, range 1.82-6.48 h) (P less than 0.05). This prolongation of the elimination half-life was due to an increased volume of distribution (Vd beta) in the obese group (42.81 1, range 35.49-51.90 l) vs 33.70 l range (17.76-50.62 l) (P less than 0.05). There was therefore no significant difference in total plasma clearance between the obese and normal groups. No correlation of ifosfamide plasma half-life was observed with total body weight (TBW) or ideal body weight (IBW). However, a significant positive correlation was observed between the percentage of IBW and plasma half-life. A strong positive correlation was observed between IBW and the plasma clearance of ifosfamide. The Vd beta correlated with both TBW and the percentage of IBW, but not with IBW itself. When Vd beta was normalised for IBW, there was a strong positive correlation with the percentage of IBW, suggesting that ifosfamide distribution into the TBW is higher than that into the IBW.
Similar articles
-
Theophylline disposition in obesity.Clin Pharmacol Ther. 1978 Apr;23(4):438-44. doi: 10.1002/cpt1978234438. Clin Pharmacol Ther. 1978. PMID: 630791
-
Cimetidine disposition in obesity.Am J Gastroenterol. 1984 Feb;79(2):91-4. Am J Gastroenterol. 1984. PMID: 6364798 Clinical Trial.
-
Digoxin disposition in obesity: clinical pharmacokinetic investigation.Am Heart J. 1981 Oct;102(4):740-4. doi: 10.1016/0002-8703(81)90100-9. Am Heart J. 1981. PMID: 7282520
-
Mitomycin, ifosfamide, and mesna in the treatment of lung cancer.Semin Oncol. 1990 Aug;17(4 Suppl 7):2-5. Semin Oncol. 1990. PMID: 2116668 Review.
-
Overview of ifosfamide in small cell and non-small cell lung cancer.Semin Oncol. 1990 Apr;17(2 Suppl 4):24-30. Semin Oncol. 1990. PMID: 2159187 Review.
Cited by
-
Pharmacology of anticancer drugs in the elderly population.Clin Pharmacokinet. 2003;42(14):1213-42. doi: 10.2165/00003088-200342140-00003. Clin Pharmacokinet. 2003. PMID: 14606930 Review.
-
What is the best size descriptor to use for pharmacokinetic studies in the obese?Br J Clin Pharmacol. 2004 Aug;58(2):119-33. doi: 10.1111/j.1365-2125.2004.02157.x. Br J Clin Pharmacol. 2004. PMID: 15255794 Free PMC article. Review.
-
Practical treatment guide for dose individualisation in cancer chemotherapy.Drugs. 1998 Dec;56(6):1019-38. doi: 10.2165/00003495-199856060-00006. Drugs. 1998. PMID: 9878990 Review.
-
Ifosfamide pharmacokinetics.Invest New Drugs. 1991 Nov;9(4):305-11. doi: 10.1007/BF00183570. Invest New Drugs. 1991. PMID: 1804803 Review.
-
The pharmacokinetics and metabolism of ifosfamide during bolus and infusional administration: a randomized cross-over study.Br J Cancer. 1998 Mar;77(6):978-84. doi: 10.1038/bjc.1998.161. Br J Cancer. 1998. PMID: 9528844 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical